Home › Companies › SYRE

Spyre Therapeutics

SYRE Rare disease Lead: Phase 2 13 Biotech Distilled articles ↓

Dermatology Immunology Protein

Most recent annual filing: 2026-04-15

Catalyst timeline

4 trackedQuarter catalyst calendar →

Spyre pipeline POC readout4Q 2026Spyre pipeline POC readout, 4Q 2026, major
SKYWAY PsA and axSpA sub-studies4Q 2026SKYWAY PsA and axSpA sub-studies, 4Q 2026, notable
SPY120/SPY130/SPY230 combinations + all monotherapies2027SPY120/SPY130/SPY230 combinations + all monotherapies, 2027, notable
SKYLINE Part B induction corporate2027SKYLINE Part B induction corporate, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

SPY001

Protein Target: α4β7, α4β7 integrin

Ulcerative Colitis Phase 2 subcutaneous Paragon Therapeutics
Crohn's Disease Phase 2 subcutaneous Paragon Therapeutics

SPY002

Protein Target: TL1A

Ulcerative Colitis Phase 2 subcutaneous Paragon Therapeutics
Crohn's Disease Phase 2 subcutaneous

SPY003

Protein Target: IL-23

Ulcerative Colitis Phase 2 subcutaneous Paragon Therapeutics
Crohn's Disease Phase 2 subcutaneous

SPY072

Protein Target: TL1A

Psoriatic Arthritis Phase 2 subcutaneous Paragon Therapeutics
Axial Spondyloarthritis Phase 2 subcutaneous Paragon Therapeutics

SPY120

Protein Target: α4β7, TL1A

Ulcerative Colitis Phase 2 subcutaneous

SPY130

Protein Target: α4β7, IL-23

Ulcerative Colitis Phase 2 subcutaneous

SPY230

Protein Target: TL1A, IL-23

Ulcerative Colitis Phase 2 subcutaneous

SPY772

SPY072 · SPY007

Protein Target: TL1A, IL-17A/F

Hidradenitis Suppurativa Preclinical NCT07766005

Discontinued (1)

SPY072 — Rheumatoid Arthritis · magnitude of effect did not meet internal bar to prioritize monotherapy development in rheumatoid arthritis

Biotech Distilled coverage (13)

2026-09-09 UPDATE: Spyre Therapeutics (SYRE) - The Third Canary Sang Flat 🔒 Paid
2026-08-25 UPDATE: Spyre Therapeutics (SYRE) - The Third Bird Sang Off-Key 🔒 Paid
2026-08-11 UPDATE: Spyre Therapeutics (SYRE) - A Fourth Target Appears 🔒 Paid
2026-08-05 UPDATE: Spyre Therapeutics (SYRE) - September Is the Whole Ballgame 🔒 Paid
2026-06-26 UPDATE: Spyre Therapeutics (SYRE) - The ATM Reloads at $88.67 🔒 Paid
2026-06-24 UPDATE: Spyre Therapeutics (SYRE) - Fairmount Sold the Top 🔒 Paid
2026-06-15 UPDATE: Spyre Therapeutics (SYRE) - The Second Canary Sang
2026-06-02 UPDATE: Spyre Therapeutics (SYRE) – Paragon Quietly Built an M&A Trapdoor for SPY003 🔒 Paid
2026-04-27 UPDATE: Spyre Therapeutics (SYRE) - The Canary Sang 🔒 Paid
2026-04-10 UPDATE: Spyre Therapeutics (SYRE) - The Binary Event is Here – April 13
2026-02-21 UPDATE: Spyre Therapeutics (SYRE) - Q4 Earnings, ECCO Data, & The $500M Shelf 🔒 Paid
2026-01-13 UPDATE: Spyre Therapeutics (SYRE) – Q1 2026 Status Check 🔒 Paid
2025-12-18 Spyre Therapeutics (SYRE): Scientific Due Diligence for Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.